# Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

> **NCT06228482** · PHASE1 · RECRUITING · sponsor: **University of California, Davis** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.

## Key facts

- **NCT ID:** NCT06228482
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-22
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06228482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06228482, "Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06228482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*